A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Study sponsor: Syndax Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2010-05Actual
Enrollment · participants8Actual
Source updated2023-07-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.